The U.S. Civilian Research & Development Foundation (CRDF) enables American companies and Eurasian scientists, engineers and organizations to explore new R&D partnerships for scientific and commercial research and develop new commercial ventures.
To meet the growing threat of drug-resistant tuberculisis, California-based SciClone Pharmaceuticals worked with a St. Petersburg, Russia-based institute on a treatment compound that could be taken orally—a more globally viable delivery method. Notably, this collaboration provided the two dozen former biological-weapons scientists with a real opportunity to transition their weapons expertise.